Xenon Pharmaceuticals Inc. - Common Stock (XENE) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2014 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
XENE on Nasdaq
Shares outstanding
76,851,274
Price per share
$44.82
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
33,561,701
Total reported value
$1,504,158,388
% of total 13F portfolios
0%
Share change
+933,337
Value change
+$43,082,093
Number of holders
160
Price from insider filings
$44.82
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Xenon Pharmaceuticals Inc. - Common Stock (XENE) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 12% +12% $277,261,485 +$30,579,986 8,824,363 +12% FMR LLC 30 Jun 2025
WELLINGTON MANAGEMENT GROUP LLP 6.2% +113% $213,557,395 +$116,084,607 4,764,779 +119% Wellington Management Group LLP 31 Dec 2025
BlackRock, Inc. 6.2% $148,914,864 4,757,709 BlackRock, Inc. 30 Jun 2025
JANUS HENDERSON GROUP PLC 5.1% $158,346,983 3,943,885 JANUS HENDERSON GROUP PLC 30 Sep 2025

As of 31 Dec 2025, 160 institutional investors reported holding 33,561,701 shares of Xenon Pharmaceuticals Inc. - Common Stock (XENE). This represents 44% of the company’s total 76,851,274 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) together control 36% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 6.6% 5,100,284 +6.9% 0% $228,594,728
Capital International Investors 4.4% 3,414,959 +7.3% 0.02% $153,058,462
JPMORGAN CHASE & CO 1.9% 1,494,032 +6.8% 0% $66,962,514
STATE STREET CORP 1.9% 1,492,550 +1.8% 0% $66,896,091
JENNISON ASSOCIATES LLC 1.7% 1,292,055 +14% 0.03% $57,909,905
Affinity Asset Advisors, LLC 1.6% 1,250,000 -11% 4% $56,025,000
WESTFIELD CAPITAL MANAGEMENT CO LP 1.6% 1,226,771 +1.7% 0.23% $54,983,876
BNP PARIBAS ASSET MANAGEMENT Holding S.A. 1.4% 1,060,221 +58% 0.05% $47,519,000
GEODE CAPITAL MANAGEMENT, LLC 1.2% 952,679 -2.5% 0% $42,692,208
Siren, L.L.C. 1.1% 812,761 0% 1.1% $36,427,948
First Turn Management, LLC 1% 799,743 0% 4.1% $35,844,481
FRANKLIN RESOURCES INC 0.99% 758,059 +8.9% 0.01% $33,976,204
Aberdeen Group plc 0.98% 750,291 +30% 0.05% $33,628,043
GOLDMAN SACHS GROUP INC 0.91% 696,047 -3.4% 0% $31,196,826
Fiera Capital Corp 0.89% 686,056 +32% 0.1% $30,749,030
AMERICAN CENTURY COMPANIES INC 0.89% 680,473 +3.2% 0.02% $30,498,884
FEDERATED HERMES, INC. 0.87% 672,237 +189% 0.05% $30,129,662
VANGUARD GROUP INC 0.86% 664,641 -22% 0% $29,789,210
Capital World Investors 0.85% 655,737 0% 0% $29,390,132
Pictet Asset Management Holding SA 0.81% 625,985 -50% 0.03% $28,010,439
LOOMIS SAYLES & CO L P 0.8% 612,032 -4.5% 0.03% $27,431,274
BARCLAYS PLC 0.78% 600,964 +440% 0.01% $26,935,207
TimesSquare Capital Management, LLC 0.69% 532,740 -4.3% 0.36% $23,877,407
DIMENSIONAL FUND ADVISORS LP 0.59% 452,147 -0.41% 0% $20,261,013
Candriam S.C.A. 0.54% 417,402 +5.2% 0.09% $18,708,754

Institutional Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 33,561,701 $1,504,158,388 +$43,082,093 $44.82 160
2025 Q3 84,320,819 $3,385,181,214 +$50,763,750 $40.15 218
2025 Q2 83,131,091 $2,602,180,922 +$191,395,540 $31.30 206
2025 Q1 76,712,560 $2,576,157,111 +$10,187,791 $33.55 206
2024 Q4 76,301,942 $2,990,887,419 +$29,910,038 $39.20 209
2024 Q3 74,889,394 $2,949,541,361 +$275,979 $39.37 202
2024 Q2 74,169,549 $2,891,734,051 +$25,968,930 $38.99 212
2024 Q1 73,488,096 $3,163,931,600 +$66,663,770 $43.05 220
2023 Q4 72,058,517 $3,319,081,625 +$473,994,183 $46.06 204
2023 Q3 61,366,625 $2,096,353,515 +$8,680,142 $34.16 180
2023 Q2 61,306,738 $2,360,645,061 +$10,880,022 $38.50 173
2023 Q1 61,134,066 $2,185,894,799 +$24,625,634 $35.79 161
2022 Q4 60,466,775 $2,384,173,156 +$38,699,727 $39.43 157
2022 Q3 57,955,532 $2,092,174,527 +$39,481,459 $36.10 151
2022 Q2 57,007,759 $1,734,195,451 +$237,069,658 $30.42 149
2022 Q1 49,043,946 $1,499,284,580 +$44,953,028 $30.57 128
2021 Q4 47,689,350 $1,489,826,062 +$453,547,589 $31.24 129
2021 Q3 34,071,867 $521,082,671 +$347,889 $15.28 113
2021 Q2 33,296,183 $619,964,580 +$2,566,015 $18.62 99
2021 Q1 32,964,044 $590,006,963 +$88,828,095 $17.90 88
2020 Q4 28,020,659 $430,912,842 -$1,905,185 $15.38 79
2020 Q3 27,927,587 $309,203,900 -$546,988 $11.07 79
2020 Q2 27,956,934 $350,580,052 +$8,434,389 $12.54 78
2020 Q1 27,692,215 $313,869,842 +$101,491,596 $11.34 69
2019 Q4 18,704,750 $245,218,634 +$22,437,621 $13.11 66
2019 Q3 16,095,522 $145,000,637 -$14,668,511 $9.01 53
2019 Q2 17,563,087 $173,174,992 -$1,947,261 $9.86 59
2019 Q1 17,736,748 $180,206,294 +$3,000,347 $10.16 61
2018 Q4 17,450,658 $110,112,206 -$24,376,594 $6.31 56
2018 Q3 17,678,662 $234,229,778 +$115,388,474 $13.20 59
2018 Q2 9,038,748 $83,159,306 +$29,134,581 $9.20 41
2018 Q1 6,350,539 $31,098,772 -$13,812,327 $4.90 35
2017 Q4 9,156,573 $25,870,113 -$498,226 $2.83 31
2017 Q3 9,321,729 $27,499,118 -$1,981,003 $2.95 31
2017 Q2 9,948,182 $31,335,126 -$1,135,510 $3.15 39
2017 Q1 10,076,433 $40,304,200 -$3,171,773 $4.00 37
2016 Q4 10,492,956 $80,798,000 +$1,871,735 $7.70 31
2016 Q3 9,943,719 $80,586,000 +$37,001,698 $8.10 31
2016 Q2 5,377,516 $32,048,000 -$2,510,463 $5.90 21
2016 Q1 5,708,042 $39,935,000 -$1,434,240 $6.99 25
2015 Q4 5,776,167 $46,491,000 +$2,273,755 $8.04 25
2015 Q3 5,476,932 $45,239,000 +$5,117,394 $8.26 25
2015 Q2 4,806,596 $55,420,000 +$3,173,766 $11.53 25
2015 Q1 4,449,844 $75,166,316 +$2,920,417 $16.86 23
2014 Q4 4,275,072 $83,141,000 +$76,655,000 $19.75 16